CSIMarket
 
Vera Therapeutics Inc   (VERA)
Other Ticker:  
 
 
Price: $41.4700 $-1.78 -4.116%
Day's High: $43.89 Week Perf: -6.16 %
Day's Low: $ 41.27 30 Day Perf: -8.88 %
Volume (M): 476 52 Wk High: $ 50.78
Volume (M$): $ 19,727 52 Wk Avg: $17.32
Open: $42.99 52 Wk Low: $5.95



 Market Capitalization (Millions $) 1,840
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -103
 Cash Flow (TTM) (Millions $) -53
 Capital Exp. (TTM) (Millions $) 0

Vera Therapeutics Inc
Vera Therapeutics Inc is a clinical-stage biotechnology company focusing on developing innovative therapies for serious unmet medical needs. The company was founded in 2019 by a team of experienced scientists and pharmaceutical professionals with extensive experience in the field of rare diseases and orphan drugs.

Vera Therapeutics is headquartered in South San Francisco, California, and has a team of over 50 employees. The company is dedicated to developing therapies for rare diseases, particularly those affecting the liver and kidneys.

The company's lead product candidate, VERA-321, is a novel treatment for primary hyperoxaluria (PH), a rare genetic disorder characterized by the overproduction of oxalate, a toxic substance that can accumulate in the kidneys and other organs, leading to severe and potentially life-threatening consequences.

VERA-321 is a small molecule inhibitor that targets the enzyme glycolate oxidase (GO), which is responsible for the synthesis of oxalate. By reducing oxalate production, VERA-321 has the potential to prevent the formation of kidney stones and other complications associated with PH.

In addition to VERA-321, Vera Therapeutics has a pipeline of other drug candidates in various stages of development, including VE-202, an inhibitor of the nuclear receptor PPAR-delta, which is being investigated for the treatment of non-alcoholic steatohepatitis (NASH), a progressive liver disease.

The company has also established partnerships with leading academic institutions and research organizations to advance its drug development programs. In 2020, Vera Therapeutics entered into a collaboration with the University of Alabama at Birmingham to study the pathophysiology of PH and identify new therapeutic targets.

Vera Therapeutics has raised over $80 million in funding to date, including a $40 million series A financing round in 2019 led by Abingworth and Amgen Ventures.

Overall, Vera Therapeutics Inc is a promising biotechnology company that is focused on developing innovative therapies for rare diseases with significant unmet medical needs. With a strong pipeline of drug candidates, a dedicated team of experts, and a commitment to advancing scientific research, Vera Therapeutics is well-positioned to make a meaningful impact in the field of rare disease therapeutics.


   Company Address: 8000 Marina Boulevard Brisbane 94005 CA
   Company Phone Number: 770-0077   Stock Exchange / Ticker: NASDAQ VERA
   VERA is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Vera Therapeutics Successfully Raises $287.5 Million in Underwritten Public Offering

Published Thu, Feb 1 2024 9:05 PM UTC



In an exciting development for the biotechnology industry, Vera Therapeutics, Inc. (Vera) has announced the successful closure of its underwritten public offering. Late-stage clinical biotech company Vera focuses on developing and commercializing groundbreaking treatments for patients with serious immunologic diseases. With the recent offering, the company raised a...

Shares

Advancing Hope: Vera Therapeutics Raises the Bar with Upsized Public Offering

Published Tue, Jan 30 2024 4:50 AM UTC

Vera Therapeutics, Inc. Sets Sights on Advancing Immunologic Disease Treatments with Upsized Public Offering
BRISBANE, Calif., Jan. 29, 2024 - Vera Therapeutics, Inc. (Vera), a leading biotechnology company focused on developing innovative treatments for serious immunologic diseases, is making significant strides towards expanding its transformative therapies. Today, the...

Clinical Study

Atacicept Demonstrates Long-Term Renal Stability in IgA Nephropathy: Insights from the Phase 2b ORIGIN Clinical Trial OLE

Published Thu, Jan 25 2024 11:30 AM UTC

IgA nephropathy is a chronic kidney disease characterized by the deposition of IgA immunoglobulins in the glomeruli. It is the most common primary glomerulonephritis worldwide, often resulting in progressive decline in renal function and necessitating renal replacement therapy. The development of effective treatment strategies that can halt or slow the progression of IgA nep...

Management Changes

Vera Therapeutics Bolsters Leadership with Industry Veterans for Transformative Drug Program Development

Published Mon, Jan 8 2024 1:02 PM UTC

Vera Therapeutics Strengthens Leadership Team with Industry Veterans to Drive Drug Program Development
Brisbane, Calif. - In a significant move to further advance its drug programs, late clinical-stage biotechnology company Vera Therapeutics, Inc. (Nasdaq: VERA) has announced the appointment of two industry veterans to its leadership team. Robert Brenner, M.D., has been ...

Vera Therapeutics Inc

VERA Therapeutics Inc. Shows Remarkable Progress, Cutting Operating Losses by Millions in Q3 2023

The stock market has seen some surprising changes in the recent reporting season at VERA, a company that shareholders didn't anticipate. However, amidst the unexpected modifications, there is a silver lining that brings hope to stockholders. The company's operating loss has significantly improved, indicating that VERA is becoming a more cost-effective competitor in its industry.
During the July to September 30, 2023 reporting season, VERA recorded an operating loss of $-21.756 million. This may seem discouraging at first glance, but when compared to the same period the previous year, where the operating loss was $-25.244 million, it becomes evident that the company has made remarkable progress. The rise in profitability is particularly impressive considering the challenging market conditions.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com